ANAKA PHARMA
Live / Allowed — Notice of allowance issued (as of 20 Jan 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 07 Apr 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99123382
- Mark type
- Design + words
- Filed
- 07 Apr 2025
- Published for opposition
- 25 Nov 2025
- Attorney of record
- Laura K. Johnson
Goods and services
- Class 005 — Pharmaceuticals: Small molecule therapeutic pharmaceuticals for the treatment of neurodevelopmental disorders, namely, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, and Down syndrome
- Class 042 — Scientific and technological services: Pharmaceutical research and development for neurodevelopment disorders
Owner
- Anaka Pharmaceuticals, Inc., Lexington, MA, US
- Anaka Pharmaceuticals, Inc., Lexington, MA, US
Prosecution history
- 20 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Nov 2025 — PUBLISHED FOR OPPOSITION
- 19 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 04 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 04 Sept 2025 — NON-FINAL ACTION E-MAILED
- 04 Sept 2025 — NON-FINAL ACTION WRITTEN
- 03 Sept 2025 — ASSIGNED TO EXAMINER
- 18 Aug 2025 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 18 Aug 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 07 Apr 2025 — APPLICATION FILING RECEIPT MAILED